Oculis Holding AG (OCS)
Fuera de horario:
Oculis Holding AG
Bahnhofstrasse 7
Zug 6300
Switzerland
41 41 711 9325
https://oculis.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 36
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Riad Sherif M.B.A., M.D. | CEO & Director | N/D | N/D | 1968 |
| Ms. Sylvia Cheung | Chief Financial Officer | N/D | N/D | 1975 |
| Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer | N/D | N/D | N/D |
| Ms. Virginia R. Dean | Chief Human Resources Officer | N/D | N/D | 1967 |
| Dr. Bastian Dehmel M.D. | Chief Development Officer | N/D | N/D | 1971 |
| Mr. Páll Ragnar Jóhannesson | Chief Business Officer | N/D | N/D | 1982 |
| Ms. Rebecca Weil | Chief Commercial Officer | N/D | N/D | N/D |
| Dr. Snehal Shah Pharm.D. | President of Research & Development | N/D | N/D | N/D |
Descripción
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Gestión corporativa
La calificación ISS Governance QuickScore de Oculis Holding AG a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
